Opinion: To get a fair deal on Wegovy, buying Novo Nordisk might not be Medicare’s worst option
Medicare and Medicaid are facing a familiar quandary: how to provide coverage for new weight loss drugs with price tags that could effectively bankrupt the federal government’s health care budget while simultaneously ensuring continuous coverage for all other health care services used by millions of Americans.
The Centers for Medicare and Medicaid Services announced in March 2024 that it would cover Wegovy (semaglutide), a new and expensive weight loss medication, for beneficiaries with cardiovascular disease and obesity. Efforts by the U.S. House of Representatives could nudge CMS to cover it more broadly for people with obesity alone.
